Financials data is unavailable for this security.
View more
Year on year Cogent Biosciences Inc 's net income fell 37.20% from a loss of 140.24m to a larger loss of 192.41m despite flat revenues.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -55.22% |
---|---|
Return on equity | -83.29% |
Return on investment | -60.02% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Cogent Biosciences Inc fell by 87.91m. Cash Flow from Financing totalled 163.54m or -- of revenues. In addition the company used 153.62m for operations while cash used for investing totalled 97.82m.
Cash flow per share | -2.45 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 3.41 |
---|---|
Tangible book value per share | 3.41 |
More ▼
Balance sheet in USDView more
Current ratio | 9.25 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼